Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC Ebiratide TFA | 99.04% | 996.23 | 1 MG
Ebiratide TFA (HOE-427) is an ACTH 4-9 derivative that directly targets the central nervous system, demonstrating memory-enhancing and neuroprotective efficacy. It enhances acetylcholine (ACh) metabolism in rat brain and exhibits anti-amnestic effects in mouse models of memory impairment.
- Acts directly on the central nervous system
- Exhibits memory-enhancing efficacy
- Enhances acetylcholine (ACh) metabolism
- Exhibits neuroprotective efficacy
- Exhibits anti-amnestic efficacy
Medchemexpress LLC Hth-01-091 Tfa | 2000209-42-5 | 98.64% | 499.43 | 1 MG
HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. It also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK, and CLK2. This compound can be used for breast cancer research.
- Potent and selective MELK inhibitor.
- Inhibits multiple kinases including PIM1/2/3, RIPK2, DYRK3, smMLCK, and CLK2.
- Suitable for breast cancer research.
Medchemexpress LLC Jbsnf-000028 Tfa | C13H14F3N3O2 | 1 ML
JBSNF-000028 TFA is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. It can reduce endogenous MNA levels in U2OS osteosarcoma cells, with an EC50 of 2.5 μM. This compound exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model and can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease.
- Orally active small molecule inhibitor of NNMT
- Reduces endogenous MNA levels in U2OS osteosarcoma cells
- Exhibits anti-obesity and anti-diabetic activities
- Useful for studying metabolic diseases like obesity, type 2 diabetes, and non-alcoholic fatty liver disease
Medchemexpress LLC Peptide R (TFA) | 98.3% | 900.08 (free base) | 1 MG
Peptide R (TFA) is a synthetic and specific CXCR4 antagonist. It shows outstanding capacities to remodel the tumor stroma and can be used for solid tumor (glioblastoma, etc.) research.
- Synthetic and specific CXCR4 antagonist
- Remodels tumor stroma
- Used for solid tumor research (glioblastoma, etc.)
- Supports cancer immunotherapy
- Supports cancer metabolism and metastasis research
- Relevant to immunology and inflammation
- Relevant to GPCR/G protein studies
- Exhibits anti-cancer properties
- Modulates microglia reactivity
- Influences self-renewal mechanisms
- Supports angiogenesis research
- Acts as an inhibitor
Medchemexpress LLC Colivelin TFA | 2803948-60-7 | 99.5% | 2759.12 | 25 MG
Colivelin TFA is a brain-penetrant neuroprotective peptide that acts as a potent activator of STAT3, suppressing neuronal death in vitro. It demonstrates long-term beneficial effects against neurotoxicity, amyloid-beta (Aβ) deposition, neuronal apoptosis, and deficits in synaptic plasticity associated with neurodegenerative diseases. This compound holds potential for the treatment of Alzheimer's disease and ischemic brain injury.
- Neuroprotective properties
- Potent activator of STAT3
- Suppresses neuronal death
- Exhibits long-term beneficial effects against neurotoxicity
- Reduces amyloid-beta (Aβ) deposition
- Prevents neuronal apoptosis
- Addresses synaptic plasticity deficits
- Potential treatment for Alzheimer's disease
- Potential treatment for ischemic brain injury
Medchemexpress LLC UNC4976 trifluoroacetate | 98.0% | 961.12 g/mol | C49H71F3N6O10 | 5 MG
UNC4976 TFA is the trifluoroacetate salt of UNC4976, a peptidomimetic positive allosteric modulator (PAM) of the CBX7 chromodomain that modulates chromodomain-nucleic acid interactions. It is supplied as a purified research compound intended for in vitro studies in epigenetics and chromatin biology.
- Trifluoroacetate salt form for improved handling and stability.
- High purity suitable for research applications (98.0%).
- Molecular formula C49H71F3N6O10 and molecular weight 961.12 g/mol.
- Available in small pack sizes for screening and assay development.
- Suitable for use in studies of chromodomain function and epigenetic modulation.
- Provided with documentation specifying identity and purity.
Medchemexpress LLC Gln-AMS TFA | 209543-57-7 | >99.85% | 588.47 | 1 MG
Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor. It inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM. It is for research use only.
- Type Ia aminoacyl-tRNA synthetase (AARS) inhibitor
- Inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM
Medchemexpress LLC Wl47 (TFA) | 99.7% | 1942.32 | 5 MG
WL47 TFA is a high-affinity cavolin-1 (CAV1) ligand that potently disrupts CAV1 oligomers. It shows selectivity for CAV1 over BSA, casein, and HEWL, and is used for studying caveolin-1 function. It is also 80% smaller in length than the original T20 parent sequence.
- High-affinity cavolin-1 (CAV1) ligand (Kd=23 nM)
- Potently disrupts CAV1 oligomers
- Exhibits selectivity for CAV1 over BSA, casein, and HEWL
- Used for studying caveolin-1 function
- 80% smaller in length than original T20 parent sequence
Medchemexpress LLC Gln-AMS TFA | 99.9% | 588.47 | 100 MG
Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor, specifically inhibiting glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM.
- Inhibits glutaminyl-tRNA synthetase (GlnRS)
- Type Ia aminoacyl-tRNA synthetase (AARS) inhibitor
- White to off-white solid
- Purity of 99.85%
- Soluble in DMSO at 100 mg/mL
- Store at -20°C under nitrogen
Medchemexpress LLC N-acetyl-L-valyl-L-alpha-glutamyl-L-isoleucyl-L-aspart-1-al | 00-00-0 | MFCD01318861 | 99.8% | 614.57 g/mol | C24H37F3N4O11 | 5 MG
Ac-VEID-CHO TFA is a peptide-derived aldehyde inhibitor of caspases used in biochemical research to study apoptosis and neurodegenerative disease mechanisms. The trifluoroacetate salt is supplied as a white to off-white solid with high purity and is suitable for assays requiring nanomolar potency against executioner caspases.
- Purity 99.8% by HPLC.
- Potent inhibition of caspase-3, caspase-6, and caspase-7 (IC50: 13.6 nM, 16.2 nM, 162.1 nM).
- Supplied as a solid, white to off-white powder.
- Soluble in water at approximately 1 mg/mL with sonication and warming.
- Storage recommendations include cold, sealed conditions to preserve stability.
- Designed for research applications in apoptosis and neurodegenerative disease models.
- Available in small research-scale quantities for assay development.
Medchemexpress LLC Egfr-in-1 Tfa | 2753348-63-7 | 99.4% | 628.60 | 1 ML
Egfr-in-1 Tfa | 2753348-63-7 | 99.4% | 628.60 | 1 ML
Medchemexpress LLC L-lysyl-L-cysteine trifluoroacetate | 97.8% | 477.38 g/mol | C13H21F6N3O7S | 5 MG
L-lysyl-L-cysteine trifluoroacetate is a dipeptide formed from lysine and cysteine, provided as a solid TFA salt for research use. The material is characterized by a reported purity, defined molecular formula and molecular weight, and specified storage recommendations for powder and solutions.
- Dipeptide composed of lysine and cysteine.
- Supplied as trifluoroacetate (TFA) salt in solid powder form.
- Reported purity 97.8%.
- Molecular formula C13H21F6N3O7S and molecular weight 477.38 g/mol.
- Available in small research quantities: 5 mg, 10 mg, 25 mg.
- Store sealed, away from moisture; powder: -80°C for 2 years, -20°C for 1 year; in solvent: -80°C for 6 months, -20°C for 1 month.
Medchemexpress LLC Ela-32(human) (tfa) | 99.9% | 3967.82 | 1 MG
ELA-32(human) TFA is a potent, high affinity apelin receptor agonist with an IC50 of 0.27 nM and a Kd of 0.51 nM. This product does not bind to GPR15 and GPR25. It activates the PI3K/AKT pathway, promoting the self-renewal of hESCs via cell-cycle progression and protein translation. Additionally, it potentiates the TGFβ pathway, priming hESCs toward the endoderm lineage, and stimulates angiogenesis in HUVEC cells.
- Potent, high affinity apelin receptor agonist
- IC50 of 0.27 nM and a Kd of 0.51 nM
- Exhibits no binding to GPR15 and GPR25
- Activates the PI3K/AKT pathway
- Promotes self-renewal of hESCs via cell-cycle progression and protein translation
- Potentiates the TGFβ pathway, priming hESCs toward the endoderm lineage
- Stimulates angiogenesis in HUVEC cells
Apexbio Technology LLC cyclo(RLsKDK) TFA(Synonyms: cyclo(RLsKDK), Cyclic peptide RLsKDK, ADAM8 inhibitor peptide, Cyclo-Arg-Leu-Ser-Lys-Asp-Lys), 5mg.
Cyclo(RLsKDK) TFA is a cyclic pentapeptide inhibitor targeting the metalloproteinase ADAM8 a transmembrane protein frequently dysregulated in pathological conditions such as inflammation cancer and neurodegenerative diseases By specifically inhibiting ADAM8 enzymatic activity cyclo(RLsKDK) TFA may modulate disease-associated cellular processes This molecule holds promise as a research tool for studying ADAM8 function and as a potential therapeutic candidate in inflammatory disorders and oncology